Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims

1. (Original) A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:



(I)

wherein X is N or CH;

R^1 is selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkenyl, C_{1-6}alkoxy, halo, cyano, perfluoro C_{1-6}alkyl, perfluoroC_{1-6}alkoxy, $-NR^4R^5$, $-(CH_2)_nNR^4R^5$, $-O(CH_2)_nOR^6$, $-O(CH_2)_nNR^4R^5$, $-CONR^4R^5$, $-CO(CH_2)_nNR^4R^5$, $-SO_2R^6$, $-SO_2NR^4R^5$, $-NR^5SO_2R^6$ and $-NR^4COR^6$;

R^2 is hydrogen, C_{1-6}alkyl, halo, cyano or perfluoroC_{1-6}alkyl;

R^3 is hydrogen or halo;

R^4 and R^5 are independently hydrogen, C_{1-6}alkyl or Het; or R^4 and R^5 together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-6}alkyl and C_{1-6}alkoxy;

R^6 is hydrogen or C_{1-6}alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C_{1-6}alkyl; and

n is 1-4.

2. (Original) A compound according to claim 1 wherein X is N.

3. (Currently Amended) A compound according ~~to any preceding claim~~ claim 1 wherein R^1 is C_{1-6}alkyl, C_{1-6}alkoxy, halo, perfluoroC_{1-6}alkoxy, $-(CH_2)_nNR^4R^5$, $-O(CH_2)_nNR^4R^5$, $-CONR^4R^5$ or $-SO_2R^6$.

4. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^2 is hydrogen, C_{1-6}alkyl, chloro or fluoro.

5. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^3 is hydrogen or fluoro.

6. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein ~~when~~ X is N, R^2 is methyl.

7. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein when X is N and R^2 is methyl, R^3 is hydrogen.

8. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^4 and R^5 are independently hydrogen, C_{1-6}alkyl or Het; or R^4 and R^5 together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine, piperazine or N-methyl piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4}alkyl or C_{1-4}alkoxy.

9. (Original) A compound according to claim 1 wherein

X is N;

R^1 is C_{1-6}alkyl, C_{1-6}alkoxy, halo, perfluoroC_{1-6}alkoxy, $-(CH_2)_nNR^4R^5$, $-O(CH_2)_nNR^4R^5$, $-CONR^4R^5$ or $-SO_2R^6$;

R^2 is hydrogen, C_{1-6}alkyl, chloro or fluoro;

R^3 is hydrogen or halo;

R^4 and R^5 are independently hydrogen, C_{1-6}alkyl or Het; or R^4 and R^5 together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine or N-methyl piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4}alkyl or C_{1-4}alkoxy.

R^6 is hydrogen or C_{1-6}alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C_{1-6}alkyl; and

n is 1-4.

10. (Original) A compound according to claim 1 selected from the list:

2-(4-methanesulfonylphenyl)-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 1);

2-(4-methoxyphenyl)-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 2);

dimethyl-[2-(4-{4-[5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl]-pyridin-2-yl}-phenoxy)-ethyl]-amine (Example 3);

4-(4-{4-[5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl]-pyridin-2-yl}-benzyl)-morpholine (Example 4);

2-(4-ethylphenyl)-4-(5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 5);

4-{4-[5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl]-pyridin-2-yl}-*N*-(tetrahydro-pyran-4-yl)-benzamide (Example 6);

2-(4-chlorophenyl)-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 7);

2-(4-trifluoromethoxyphenyl)-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 8);

2-{4-(2-pyrrolidin-1-yl-ethoxy)-phenyl}-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 9); and

2-(4-fluorophenyl)-4-(5-(6-methyl)-pyridin-2-yl-3H-[1,2,3]triazol-4-yl)-pyridine (Example 10);

and pharmaceutically acceptable salts, solvates and derivatives thereof.

11. (Currently Amended) A pharmaceutical composition comprising a compound defined in ~~any preceding claim~~ claim 1 and a pharmaceutically acceptable carrier or diluent.

12 -15 (Cancelled)

16. (New) A method of treatment or prophylaxis of a disorder mediated by the ALK5 receptor in mammals selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV), hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis, mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis, endometriosis, keloids and restenosis by administering a compound according to claim 1.